Daniel Kraft, MD

Daniel Kraft, MD

Stanford, California, United States
42K followers 500+ connections

Join to follow

About

Stanford and Harvard trained Physician-Scientist, innovator and investor with over 25…

Articles by Daniel

See all articles

Activity

Join now to see all activity

Experience

  • NextMed Health Graphic

    NextMed Health

  • -

    San Francisco Bay Area

  • -

  • -

  • -

  • -

    NASA-Ames Research Park

  • -

  • -

  • -

    San Francisco Bay Area

  • -

  • -

  • -

    Palo Alto, CA

  • -

  • -

    Hotel Del Coronado, San Diego

  • -

  • -

  • -

    California Air National Guard

  • -

  • -

    6 Part Series

  • -

  • -

    Palo Alto, CA

  • -

  • -

  • -

    Boston, MA

  • -

Education

  • Stanford University School of Medicine Graphic

    Stanford University School of Medicine

    -

    Activities and Societies: The American Society of Hematology (ASH) American Society for Bone Marrow Transplantation (ASBMT)

    Completed fellowship in pediatric hematology/oncology and adult bone marrow transplantation.
    Postdoctoral research in the laboratory of Dr. Irving L. Weissman. Research on the hematopoietic stem cell niche and novel approaches to conditioning regimens was published in journals including Nature and Science.
    -Biodesign Program: Invented the MarrowMiner technology.

  • -

    Four-year combined Harvard residency at Massachusetts General Hospital & Boston Children's Hospital. Board certified in Internal Medicine & Pediatrics.

  • -

    Activities and Societies: Howard Hughes Medical Institute (HHMI) Research Fellow

Publications

  • The MarrowMiner: A Novel Minimally Invasive and Effective Device for the Harvest of Bone Marrow

    Biology of Blood and Bone Marrow Transplantation

    Bone marrow (BM) is a rich source of hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), and other important stem/progenitor cells. It is the traditional source of cells used in hematopoietic cell transplantation, which is a proven curative treatment for many blood and immune diseases. BM-derived cells have also been shown to have other diverse clinical uses and are increasingly being used in orthopedic medicine, regenerative medicine, and gene therapy applications. Traditional…

    Bone marrow (BM) is a rich source of hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), and other important stem/progenitor cells. It is the traditional source of cells used in hematopoietic cell transplantation, which is a proven curative treatment for many blood and immune diseases. BM-derived cells have also been shown to have other diverse clinical uses and are increasingly being used in orthopedic medicine, regenerative medicine, and gene therapy applications. Traditional methods for harvesting BM are crude, tedious, time-consuming, and expensive, requiring multiple bone punctures under general anesthesia with serial small-volume aspirates often diluted with peripheral blood. The MarrowMiner (MM) is a novel device designed for rapid and minimally invasive BM harvest. Here we show the safety and efficacy of the MM in both preclinical and clinical settings. In a large-animal porcine model, the MM enabled effective BM collection with similar total nucleated cell collection and increased colony formation compared with standard methods. The MM was subsequently evaluated in a clinical study showing effective and complication-free anterior and posterior BM collection of 20 patients under only local anesthesia or light sedation. Increased total nucleated and mononucleated cell collection was achieved with the MM compared with standard methods in the same patients. Importantly, stem cell content was high with trends toward increased HSC, MSC, and endothelial progenitor cells with similar T cell content. Given the MM is a novel device approved by the US Food and Drug Administration, enabling safe, effective, and minimally invasive harvest of BM, we anticipate rapid adoption for various applications.

    See publication

  • The Future of Medicine: 12 innovations that will revolutionize the future of medicine

    National Geographic

    Cover Story for the January 2019 Edition of The National Geographic:

    Analytics-enabled, individualized attention will not just treat disease, but increasingly, prevent it.

    See publication

  • Our Health is In Our Hands

    WIRED

    See publication

  • Clonal precursor of bone, cartilage, and hematopoietic niche stromal cells

    PNAS

    Organs are composites of tissue types with diverse developmental origins, and they rely on distinct stem and progenitor cells to meet physiological demands for cellular production and homeostasis. How diverse stem cell activity is coordinated within organs is not well understood. Here we describe a lineage-restricted, self-renewing common skeletal progenitor (bone, cartilage, stromal progenitor; BCSP) isolated from limb bones and bone marrow tissue of fetal, neonatal, and adult mice. The BCSP…

    Organs are composites of tissue types with diverse developmental origins, and they rely on distinct stem and progenitor cells to meet physiological demands for cellular production and homeostasis. How diverse stem cell activity is coordinated within organs is not well understood. Here we describe a lineage-restricted, self-renewing common skeletal progenitor (bone, cartilage, stromal progenitor; BCSP) isolated from limb bones and bone marrow tissue of fetal, neonatal, and adult mice. The BCSP clonally produces chondrocytes (cartilage-forming) and osteogenic (bone-forming) cells and at least three subsets of stromal cells that exhibit differential expression of cell surface markers, including CD105 (or endoglin), Thy1 [or CD90 (cluster of differentiation 90)], and 6C3 [ENPEP glutamyl aminopeptidase (aminopeptidase A)]. These three stromal subsets exhibit differential capacities to support hematopoietic (blood-forming) stem and progenitor cells. Although the 6C3-expressing subset demonstrates functional stem cell niche activity by maintaining primitive hematopoietic stem cell (HSC) renewal in vitro, the other stromal populations promote HSC differentiation to more committed lines of hematopoiesis, such as the B-cell lineage. Gene expression analysis and microscopic studies further reveal a microenvironment in which CD105-, Thy1-, and 6C3-expressing marrow stroma collaborate to provide cytokine signaling to HSCs and more committed hematopoietic progenitors. As a result, within the context of bone as a blood-forming organ, the BCSP plays a critical role in supporting hematopoiesis through its generation of diverse osteogenic and hematopoietic-promoting stroma, including HSC supportive 6C3(+) niche cells.

    See publication

  • Endochondral ossification is required for haematopoietic stem-cell niche formation

    NATURE

    Charles K. F. Chan, Ching-Cheng Chen, Cynthia A. Luppen, Jae-Beom Kim, Anthony T. DeBoer, Kevin Wei, Jill A. Helms, Calvin J. Kuo, Daniel L. Kraft, Irving L. Weissman. Endochondral ossification is required for haematopoietic stem-cell niche formation. Nature. Jan 2009;457(7228):490-494.

    Other authors
    See publication

  • Efficient Transplantation via Antibody-based Clearance of Hematopoietic Stem Cell Niches

    Science

    We demonstrate that administration of a depleting antibody specific for c-kit leads to the highly efficient removal of host hematopoietic stem cells (HSCs) and high levels of donor HSC chimerism following transplantation.
    Upon intravenous transplantation, hematopoietic stem cells (HSCs) can home to specialized niches, yet most HSCs fail to engraft unless recipients are subjected to toxic preconditioning. Here, we provide evidence that, aside from immune barriers, donor HSC engraftment is…

    We demonstrate that administration of a depleting antibody specific for c-kit leads to the highly efficient removal of host hematopoietic stem cells (HSCs) and high levels of donor HSC chimerism following transplantation.
    Upon intravenous transplantation, hematopoietic stem cells (HSCs) can home to specialized niches, yet most HSCs fail to engraft unless recipients are subjected to toxic preconditioning. Here, we provide evidence that, aside from immune barriers, donor HSC engraftment is restricted by occupancy of appropriate niches by host HSCs. Administration of ACK2, an antibody that blocks c- kit function, led to the transient removal of >98% of endogenous HSCs in immunodeficient mice. Subsequent transplantation of these animals with donor HSCs led to chimerism levels of up to 90%. Extrapolation of these methods to humans may enable mild but effective conditioning regimens for transplantation.

    See publication

  • Differentiation of CD3-4-8- human fetal thymocytes in vivo: characterization of a CD3-4+8- intermediate.

    Journal of Experimental Medicine (J Exp Med)

    Human thymocyte differentiation was examined by injecting fetal thymic progenitor populations into human thymic xenografts in SCID-hu mice. Thymic progenitors were fluorescently labeled with the lipophilic dye PKH2. The phenotypes of their progeny could be identified by flow cytometric analysis of cells with a very high fluorescent PKH2 signal. Intrathymic injection of purified triple negative (TN) CD3-4-8- thymocytes resulted in the sequential appearance of CD3-4+8-, CD3-4+8+, and CD3+4+8+…

    Human thymocyte differentiation was examined by injecting fetal thymic progenitor populations into human thymic xenografts in SCID-hu mice. Thymic progenitors were fluorescently labeled with the lipophilic dye PKH2. The phenotypes of their progeny could be identified by flow cytometric analysis of cells with a very high fluorescent PKH2 signal. Intrathymic injection of purified triple negative (TN) CD3-4-8- thymocytes resulted in the sequential appearance of CD3-4+8-, CD3-4+8+, and CD3+4+8+ cells, with the subsequent appearance of small numbers of phenotypically mature CD3+4+8- and CD3+4-8+ cells over a 4-d period. Sorted CD3-4+8- thymocytes injected intrathymically rapidly differentiated to CD4+8+ cells. CD4+8+ fetal thymocytes in cell cycle differentiated into phenotypically mature CD3+4+8- and CD3+4-8+ populations, whereas nondividing CD4+8+ cells failed to differentiate after intrathymic transfer. The number of cell divisions that occurred between the injection of TN thymocytes and their progeny at different time points was estimated based on the decrease in the intensity of the PKH2 label. The average length of the cell cycle for the TN population was calculated to be 24 h. The SCID-hu model thus provides a useful tool for studying the kinetics of cell division and differentiation of human thymocytes in vivo.

    See publication

Patents

  • System and methods for the production of personalized drug products

    Issued US11319125B2

    A system for producing a personalized drug product for an individual patient

    See patent

  • MHC-Antigen Arrays for Detection and Characterization of Immune Responses

    Issued US US 7,902,121 B2

    Compositions and methods are provided for profiling of T cells, in which cells are profiled with respect to their expression of antigen receptors, and ability to respond to external stimulus in the microenvironment. External stimuli include cell-cell interactions, response to factors, and the like. The cells are arrayed on a planar or three-dimensional substrate through binding to immobilized or partially diffused MHC-antigen complexes. Additional probes may also be arrayed in combination with…

    Compositions and methods are provided for profiling of T cells, in which cells are profiled with respect to their expression of antigen receptors, and ability to respond to external stimulus in the microenvironment. External stimuli include cell-cell interactions, response to factors, and the like. The cells are arrayed on a planar or three-dimensional substrate through binding to immobilized or partially diffused MHC-antigen complexes. Additional probes may also be arrayed in combination with the MHC-antigen complexes, including signaling cues that act to regulate cell responses, adhesion molecules, differentiation factors, etc. After the cells are arrayed, they may be characterized for expression of antigen receptor and other phenotypic attributes, e.g. expression of other cell surface markers; or maintained in culture for a period of time sufficient to determine the response to a stimulus of interest.

    Other inventors
    See patent

  • SELECTIVE IMMUNODEPLETION OF ENDOGENOUS STEM CELL NICHE FOR ENGRAFTMENT

    Issued US 20100226927

    The present invention provides a clinically applicable method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring radiotherapy or chemotherapy, and without development of GVHD or graft rejection. Aspects of the present invention are based on the discovery that the depletion of the endogenous stem cell niche facilitates efficient engraftment of stem cells into that niche. In particular, the present invention combines the…

    The present invention provides a clinically applicable method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring radiotherapy or chemotherapy, and without development of GVHD or graft rejection. Aspects of the present invention are based on the discovery that the depletion of the endogenous stem cell niche facilitates efficient engraftment of stem cells into that niche. In particular, the present invention combines the use of selective ablation of endogenous stem cells, in combination with the administration to the recipient of exogenous stem cells, resulting in efficient, long-term engraftment and tolerance.

    See patent

  • Device and method for rapid aspiration and collection of body tissue from within an enclosed body space

    Issued US 7,462,181

    Minimally invasive device and system for the harvest of bone marrow.

    See patent

  • Selective Immunodepletion of Endogenous Stem Cell Niche for Engraftment

    US 10072091

Honors & Awards

  • The 2019 Healthcare Technology Influencers List

    HealthTech

    https://healthtechmagazine.net/article/2019/09/2019-healthcare-technology-influencers-list-healthtechs-30-must-follow-health-it-influencers

  • Bold Innovator for Conquering Cancer Xprize - Top Ranked New Xprize Proposal

    XPRIZE

    http://www.xprize.org/visioneers/teams/conquering-cancer

    http://3blmedia.com/News/XPRIZE-Visioneers-2016-Summit-Declares-Deloittes-Conquering-Cancer-XPRIZE-Ready-Launch

  • Winner: Top 50 in Digital Health

    Rock Health, Goldman Sachs, Fenwick & West

    http://www.top50indigitalhealth.com/

    "Each year fifty of the leading entrepreneurs, investors, technologists, reporters, and providers dedicated to bringing technological advancements to healthcare are recognized at the Top 50 in Digital Health Dinner hosted by Rock Health, Fenwick & West, and Goldman Sachs.

    Within the Top 50, a number of individuals and organizations are awarded through nominations from the digital health community for making exceptional progress in driving…

    http://www.top50indigitalhealth.com/

    "Each year fifty of the leading entrepreneurs, investors, technologists, reporters, and providers dedicated to bringing technological advancements to healthcare are recognized at the Top 50 in Digital Health Dinner hosted by Rock Health, Fenwick & West, and Goldman Sachs.

    Within the Top 50, a number of individuals and organizations are awarded through nominations from the digital health community for making exceptional progress in driving resources, attention, and innovation toward a massively better healthcare system. From writing healthcare policy to steering corporate acquisitions to moving technology from the bench to the bedside, we want to honor the people and organizations making digital health thrive. We're proud to announce the winners of the Top 50 in Digital Health."

  • The Top Ten Internet-Smart Doctors in the World 2013

    InternetMedicine.com

    #2 on the list... http://internetmedicine.com/2014/02/24/the-top-ten-internet-smart-doctors-in-the-world-2013/

  • PharmaVoice 100

    PharmaVoice

    PharmaVOICE 100 is an annual list of individuals recognized for their positive contributions to the life-sciences industry. http://www.pharmavoice.com/archives/article.esiml?id=2735

  • 40 of the Smartest People in Healthcare

    Becker's Hospital Review

    "As providers, payers and policymakers have searched for the best way to contain costs while improving quality of care, certain individuals stand out as having the intellect and acumen needed to spearhead successful reform. Here are 40 of the smartest people in healthcare today." http://www.beckershospitalreview.com/lists/40-of-the-smartest-people-in-healthcare.html

  • 2011 Leadership in Innovation Award

    ABL- Adaptive Business Leaders

    ABL- ''Abby Award'' for Leadership in Innovation.

  • NIH K08 Clinical Scientist Investigator Award

    National Institutes of Health

  • NASA Astronaut (Mission Specialist) Selection Finalist

    -

    http://www.spacefacts.de/bios/candidates/nasa19/english/kraft_daniel.htm

  • United States Air Force Meritorious Achievement Medal

    USAF

    As a member of the Massachusetts Air National Guard: 104th Fighter Wing

  • Howard Hughes Medical Institute (HHMI) Fellow

    HHMI

    HHMI Medical Training Fellowship

Organizations

  • Aspen Institute

    Healthcare Innovation Fellow (Inaugural Class)

    - Present

    Member of Aspen Institute 2015 Inaugural Class of Health Innovator Fellows and a member of the Aspen Global Leadership Network.

  • Kauffman Fellows Program - Center for Venture Education

    Class 13 Fellow

    - Present

    http://KFP.org Center for Venture Education

  • Society of Kauffman Fellows

    -

Recommendations received

1 person has recommended Daniel

Join now to view

More activity by Daniel

View Daniel’s full profile

  • See who you know in common
  • Get introduced
  • Contact Daniel directly
Join to view full profile

Other similar profiles

Explore more posts

Explore collaborative articles

We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.

Explore More

Others named Daniel Kraft, MD

1 other named Daniel Kraft, MD is on LinkedIn

See others named Daniel Kraft, MD

Add new skills with these courses

See all courses